AU614607B2 - Use of and agent for reducing side effects of tnf - Google Patents
Use of and agent for reducing side effects of tnf Download PDFInfo
- Publication number
- AU614607B2 AU614607B2 AU34064/89A AU3406489A AU614607B2 AU 614607 B2 AU614607 B2 AU 614607B2 AU 34064/89 A AU34064/89 A AU 34064/89A AU 3406489 A AU3406489 A AU 3406489A AU 614607 B2 AU614607 B2 AU 614607B2
- Authority
- AU
- Australia
- Prior art keywords
- tnf
- paf
- composition
- side effects
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000000694 effects Effects 0.000 title claims abstract description 13
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 102000018594 Tumour necrosis factor Human genes 0.000 claims description 5
- 108050007852 Tumour necrosis factor Proteins 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 4
- SCSIRWUYQVAIRL-UHFFFAOYSA-N ac1miw90 Chemical compound C1=2CC(C(=O)N(CCC)CCC)CC=2SC(N2C(C)=NN=C2CN=2)=C1C=2C1=CC=CC=C1Cl SCSIRWUYQVAIRL-UHFFFAOYSA-N 0.000 claims description 3
- FWYVRZOREBYLCY-UHFFFAOYSA-N bepafant Chemical compound C1C=2SC=3N4C(C)=NN=C4CN=C(C=4C(=CC=CC=4)Cl)C=3C=2CC1C(=O)N1CCOCC1 FWYVRZOREBYLCY-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract description 11
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract description 9
- 231100001274 therapeutic index Toxicity 0.000 abstract 1
- 239000013543 active substance Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002226 simultaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Paper (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3816169A DE3816169A1 (de) | 1988-05-11 | 1988-05-11 | Verwendung und mittel zur verminderung der nebenwirkungen von tnf |
| DE3816169 | 1988-05-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3406489A AU3406489A (en) | 1989-11-16 |
| AU614607B2 true AU614607B2 (en) | 1991-09-05 |
Family
ID=6354207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU34064/89A Ceased AU614607B2 (en) | 1988-05-11 | 1989-05-05 | Use of and agent for reducing side effects of tnf |
Country Status (13)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3735525C2 (de) * | 1987-10-20 | 1997-02-20 | Korth Ruth Maria | Verfahren zur Bestimmung der Wirksamkeit von paf-Acether-Rezeptor-Antagonisten |
| GB8926611D0 (en) * | 1989-11-24 | 1990-01-17 | Xenova Ltd | Compound and its use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3786456T2 (de) * | 1986-10-16 | 1994-02-03 | Biogen Inc | Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen. |
-
1988
- 1988-05-11 DE DE3816169A patent/DE3816169A1/de not_active Withdrawn
-
1989
- 1989-05-01 KR KR1019890005809A patent/KR900017592A/ko not_active Withdrawn
- 1989-05-03 ES ES89107969T patent/ES2042864T3/es not_active Expired - Lifetime
- 1989-05-03 DE DE8989107969T patent/DE58901920D1/de not_active Expired - Lifetime
- 1989-05-03 AT AT89107969T patent/ATE78695T1/de not_active IP Right Cessation
- 1989-05-03 EP EP89107969A patent/EP0341558B1/de not_active Expired - Lifetime
- 1989-05-03 ZA ZA893259A patent/ZA893259B/xx unknown
- 1989-05-04 CA CA000598696A patent/CA1336825C/en not_active Expired - Fee Related
- 1989-05-05 DK DK220789A patent/DK220789A/da not_active Application Discontinuation
- 1989-05-05 IL IL90206A patent/IL90206A0/xx unknown
- 1989-05-05 HU HU892180A patent/HUT52381A/hu unknown
- 1989-05-05 AU AU34064/89A patent/AU614607B2/en not_active Ceased
- 1989-05-06 JP JP1113985A patent/JP2709139B2/ja not_active Expired - Lifetime
-
1992
- 1992-08-06 GR GR920401724T patent/GR3005387T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK220789A (da) | 1989-11-12 |
| JPH0276825A (ja) | 1990-03-16 |
| ZA893259B (en) | 1991-01-30 |
| DK220789D0 (da) | 1989-05-05 |
| DE3816169A1 (de) | 1989-11-23 |
| IL90206A0 (en) | 1989-12-15 |
| ATE78695T1 (de) | 1992-08-15 |
| EP0341558A2 (de) | 1989-11-15 |
| EP0341558A3 (en) | 1990-05-09 |
| AU3406489A (en) | 1989-11-16 |
| EP0341558B1 (de) | 1992-07-29 |
| GR3005387T3 (enrdf_load_stackoverflow) | 1993-05-24 |
| JP2709139B2 (ja) | 1998-02-04 |
| KR900017592A (ko) | 1990-12-19 |
| HUT52381A (en) | 1990-07-28 |
| DE58901920D1 (de) | 1992-09-03 |
| CA1336825C (en) | 1995-08-29 |
| ES2042864T3 (es) | 1993-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2318849T3 (es) | Composiciones farmaceuticas para el suministro controlado de receptores solubles. | |
| US4734279A (en) | Combination of immunoglobulins with therapeutic agents | |
| Prins et al. | Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients | |
| JP2002509529A (ja) | Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法 | |
| AU4787996A (en) | Calcitonin salmon analogues, their preparation, medicinal useand use as analytical agents | |
| US5550153A (en) | Method for treating heartworm-infected canines | |
| RU2002105485A (ru) | Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α) | |
| AU614607B2 (en) | Use of and agent for reducing side effects of tnf | |
| CA2408797A1 (en) | Treatment of breast cancer | |
| AU715260B2 (en) | TNF receptor and steroid hormone in a combined therapy | |
| CA2386583A1 (en) | Novel combination for the treatment of sexual dysfunction | |
| JP3587851B2 (ja) | Ｔｎｆ誘発病状の治療におけるベンジダミンの使用 | |
| JP2770911B2 (ja) | 抗ウイルス医薬組成物 | |
| CA2368352A1 (en) | Method for treating neurodegeneration | |
| Schirger et al. | Prazosin—new Hypertensive Agent: A Double-Blind Crossover Study in the Treatment of Hypertension | |
| JP3041051B2 (ja) | 遺伝子治療における神経性炎症の予防のためのｎｋ−１レセプターアンタゴニスト | |
| JP2002529515A5 (enrdf_load_stackoverflow) | ||
| US7012060B1 (en) | TNF receptor and steroid hormone in a combined therapy | |
| ES2935703T3 (es) | Metotrexato para uso como medicamento | |
| DE60316407T2 (de) | Tumornekrosefaktor in kombination mit interferon zur behandlung und/oder verhinderung einer demyelinisierenden krankheit | |
| ES2239954T3 (es) | Terapia contra el melanoma. | |
| AU777456B2 (en) | CML therapy | |
| CA1332222C (en) | Pharmaceutical composition for preventing and treating diseases caused by primary immune deficiences | |
| US5942224A (en) | Therapeutic agent for cat respiratory diseases and method of treatment using the same | |
| JP2609882B2 (ja) | 脱髄性疾患治療薬 |